ArticleFrontiers in oncology2026
Ultrasound radiomics for preoperative evaluation of Ki-67 proliferation index in papillary thyroid carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the predictive value of radiomics features, ultrasound (US), and gene mutation status based on interpretable random forest (RF) models for predicting high Ki-67 expression in papillary thyroid carcinoma (PTC). Methods: This retrospective analysis included 627 patients with surgically confirmed PTC who underwent testing for BRAF V600E and TERT promoter mutations, as well as immunohistochemical assessment of Ki-67 expression from December 2015 to June 2023. The eligible patients were randomly divided into a training set and a testing set at a ratio of 7:3 according to their binary Ki-67 expression status. A random forest model was constructed using both individual and combined ultrasound radiomics features, conventional ultrasound features, and genetic mutation status to predict high Ki-67 expression in PTC. Using AUC, Brier score and decision curve analysis to verify the clinical utility of the model. Result: The Rad+US+Gene model demonstrated superior predictive accuracy for high Ki-67 expression, achieving the highest accuracy and AUC, along with the lowest Brier score. In the testing cohort, the Rad+US+Gene model attained an accuracy of 0.883, outperforming Rad+US, US and Rad (0.851). Its AUC reached 0.904, markedly exceeding those of Rad+US (0.854), US (0.823), and Rad (0.851). Regarding calibration, the Rad+US+Gene model also yielded the lowest Brier score (0.0822), compared with Rad+US (0.1073), US (0.1061), and Rad (0.1232), indicating superior predictive accuracy and stability. Conclusion: The integrated model combining radiomics, US features and genetic mutations achieves favorable predictive performance, presenting a new method for the preoperative assessment of Ki-67 expression level in PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.